Summit Therapeutics co-CEO exercises 300K-share option
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Summit Therapeutics Inc. co-CEO Mahkam Zanganeh exercised an option for 300,000 common shares at $1.06 per share on November 20, 2026. Her direct common-stock holdings after the exercise were 831,000 shares, and the reported option balance was 500,000.
Indirect holdings reported after the transaction were 25,824,474 shares in the Mahkam Zanganeh Revocable Trust, 76,680 held by an immediate family member, 10,199,776 in the Shaun Zanganeh Irrevocable Trust and 573,883,879 held by her spouse. Zanganeh disclaimed beneficial ownership of the reported securities except to the extent of her pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F3 | 300,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 300,000 | $1.06 | $318K |
| Holding | Common Stock F2 | -- | -- | -- |
| Holding | Common Stock F2 | -- | -- | -- |
| Holding | Common Stock F2 | -- | -- | -- |
| Holding | Common Stock F2 | -- | -- | -- |
Footnotes (3)
- F1. On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
- F2. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F3. The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.
Key Figures
Key Terms
pecuniary interest financial
performance criteria technical
service-based vesting requirements technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.